FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Amkr: Results/outlook Ahead Of Consensus, Supported By Auto/industrial Recovery

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Q1 sales of $1.68B (+27% Y/Y) exceeded Street expectations ($1.65B) along with EPS of $0.33 (vs. Street $0.24), with Q2 revenue/EPS guidance of $1.80B/$0.47 representing larger beats vs. expectations of $1.74B/$0.31, respectively. Q2 gross margin was guided to 15.0%, above consensus of 14.8%. We point to Auto/Industrial strength as the most important result during Q1, with the segment's 28% Y/Y growth continuing to show acceleration over the past several quarters following a long period of weakness. Tariff reductions should help, though emerging issues like the Strait of Hormuz closure and ongoing memory shortage could challenge this recovery thesis in the coming quarters. AMKR lowered its 2026 capex outlook slightly from ~$3.0B to ~$2.75B, a total that remains substantial as it looks to support TSMC's ambitions in Arizona, which will likely necessitate borrowing/higher interest costs. We consider the reduced capex forecast to reflect a narrowing of expectations rather than lower demand projections.

相关文章

International

日本3月份失业率小幅上升至2.7%。

根据日本政府周二公布的数据,3月份日本失业率小幅上升至2.7%,高于上月的2.6%。 数据显示,经季节性调整后,3月份就业人数从2月份的6827万人略微下降至6815万人,而失业人数则从上月的185万人增加至186万人。

$^N225
Asia

市场传闻:受美国定价模式影响,日本或将错失新药供应

据《日经新闻》周二报道,由于美国一项定价模式可能将美国药品价格与日本在最惠国待遇(MFN)下的较低价格挂钩,日本或将错失突破性药物。 该报称,根据这项计划,美国将参考包括日本在内的其他国家的药品价格来确定联邦医疗保险(Medicare)和医疗补助(Medicaid)的报销标准,但企业可以通过不在日本上市产品来规避这一限制。 该报指出,这可能导致制药公司推迟或放弃进入日本市场,而日本则可能面临药品价格上涨和社会保险成本增加的压力。 报道称,行业组织正在敦促日本重新评估其定价规则,以使创新药物的价格与国际水平接轨,并在专利期内维持这一水平。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息被认为是来自可靠来源,但可能包含传闻和推测。准确性无法保证。)

$^N225
Asia

Echo IQ 将基于人工智能的决策支持软件部署到美国医疗系统中

据周二提交给澳大利亚证券交易所的文件显示,Echo IQ(ASX:EIQ)已将其基于人工智能的决策支持软件EchoSolv AS部署到纽约西奈山医疗系统,用于评估严重主动脉瓣狭窄。 文件还指出,该公司正继续与美国其他医院洽谈该产品的潜在应用机会。

$ASX:EIQ